Title	Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease
Authors	Simeng Lin[1,2]*, Eilis Hannon[3]*, Mark Reppell[4], Jeffrey F. Waring[4], Nizar Smaoui[4], Valerie Pivorunas[4], Heath Guay[4], Neil Chanchlani[1,2], Claire Bewshea[2], Benjamin Y H Bai[5,6], Nicholas A Kennedy[1,2], James R Goodhand[1,2], Jonathan Mill[3]*, Tariq Ahmad[1,2]*, PANTS Consortium *denotes shared authorship
Affiliations	[1]Gastroenterology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK [2]Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK [3]University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK [4]AbbVie Inc., Chicago, IL, USA; [5]Genomics of Inflammation and Immunity Group, Wellcome Sanger Institute, Hinxton, UK; [6]Postgraduate School of Life Sciences, University of Cambridge, Cambridge, UK
Address for correspondence	Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK, tariq.ahmad1@nhs.net
Key words	DNA methylation, Epigenetics, Anti-TNF, Crohn's disease, IBD
Running title	DNA methylation changes associated with anti-TNF drug concentration
Word count	6,777

3
4

Abstract

Background and Aims

Anti-TNF treatment failure in patients with inflammatory bowel disease (IBD) is common and

frequently related to low drug concentrations.

In order to identify patients who may benefit from dose optimisation at the outset of anti-TNF

therapy, we sought to define epigenetic biomarkers in whole blood at baseline associated with anti-

TNF drug concentrations at week 14.

Methods

DNA methylation from 1,104 whole blood samples from the Personalised Anti-TNF Therapy in

Crohn's disease (PANTS) study were assessed using the Illumina EPIC Beadchip at baseline, weeks 14,

30 and 54. We compared DNA methylation profiles in anti-TNF-treated patients who experienced

primary non-response at week 14 and were not in remission at week 30 or 54 (infliximab n = 99,

adalimumab n = 94) with patients who responded at week 14 and were in remission at week 30 or

54 (infliximab n = 99, adalimumab n = 93).

Results

Overall, between baseline and week 14, we observed 4,999 differentially methylated probes (DMPs)

annotated to 2376 genes following anti-TNF treatment. Pathway analysis identified 108 significant

gene ontology terms enriched in biological processes related to immune system processes and

responses.

Epigenome-wide association (EWAS) analysis identified 323 DMPs annotated to 210 genes at

baseline associated with higher anti-TNF drug concentrations at week 14. Of these, 125 DMPs

demonstrated shared associations with other common traits (proportion of shared CpGs compared

to DMPs) including body mass index (23.2%), followed by CRP (11.5%), smoking (7.4%), alcohol

consumption per day (7.1%) and IBD type (6.8%). EWAS of primary non-response to anti-TNF

identified 20 DMPs that were associated with both anti-TNF drug concentration and primary non-

response to anti-TNF with a strong correlation of the coefficients (Spearman's rho = -0.94, p < 0.001).

Conclusion

Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at

week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF

therapy.

Introduction

Anti-TNF therapies remain the most effective treatment to induce and maintain remission in

patients with Crohn's disease[1,2]. Successful treatment leads to mucosal healing, reduced surgeries,

and improvements in quality of life[3]. Unfortunately, anti-TNF treatment failure is common, with a

quarter of patients experiencing primary non-response, and one-third of initial responders losing

response by the end of the first year[4].

In the Personalised Anti-TNF Therapy in Crohn's Disease study (PANTS), whilst loss of response was

associated with the formation of anti-drug antibodies that were predicted by carriage of the HLA-

DQA1*05 haplotype and mitigated by concomitant immunomodulator use, the only modifiable

factor associated with primary non-response at week 14 was low anti-TNF drug concentration[5,6].

In this regard early dose optimisation reportedly improves anti-TNF response rates[7,8]. Whilst the

biology of non-response is complex, an ability to predict primary non-response may inform

treatment choice and identify individuals who may benefit from dose optimisation during induction

therapy.

Heterogeneity of response to anti-TNF therapies has led to a drive to understand the molecular

mechanisms underlying treatment failure in anti-TNF therapy. Increased mucosal expression of

oncostatin M (*OSM*)[9,10] and triggering receptor expressed on myeloid cells (*TREM-1*)[11,12] have been

identified as potential biomarkers predicting non-response to anti-TNF treatment. Drawing

conclusions across studies is difficult, however, due to differences in study design, improvements in

experimental and computational methods through time and critically, confounding by cellular

heterogeneity with contradictory results between whole blood and intestinal biopsies[13]. Clinical

translation of tissue biomarkers has also further been limited by accessibility and processing costs[14].

DNA methylation, an epigenetic modification to DNA, can influence gene expression via disruption of

transcription factor binding and recruitment of methyl-binding proteins that initiate chromatin

compaction and gene silencing[15,16]. Despite being traditionally regarded as a mechanism of

transcriptional repression, DNA methylation is actually associated with both increased and

decreased gene expression[17], and other genomic functions including alternative splicing and

promoter usage[18]. DNA methylation can be influenced by both genetic[19] and environmental

factors[20], changing with age[21] and exposures such as cigarette smoking[22]. The development of

standardised assays for quantifying DNA methylation across the genome at single-base resolution in

large numbers of samples has enabled researchers to perform epigenome-wide association studies

(EWAS) aimed at identifying methylomic variation associated with exposures and traits[23]. EWAS

analyses are inherently more complex to design and interpret than genetic association studies; the

dynamic nature of epigenetic processes means that a range of potentially important confounding

factors (including tissue or cell type, age, sex, and lifestyle exposures) need to be considered in

between-group comparisons[24].

Previous studies of DNA methylation using whole blood or individual purified cell types have

identified differentially methylated positions (DMPs) between patients with active and inactive IBD

and healthy controls[25,26]. Pharmacoepigenomics is the application of epigenetics to understand

interindividual differences in the response to therapeutic drugs[27]. DNA methylation sites from whole

blood have been identified as effective biomarkers predicting treatment response to methotrexate

and anti-TNF in patients with rheumatoid arthritis[28,29].

In this study we used a powerful intra-individual study design to identify changes in DNA

methylation associated with anti-TNF drug treatment, profiling 385 patients at baseline and weeks

14, 30 and 54 post treatment initiation. In order to identify patients who may benefit from dose

optimisation at the outset of anti-TNF therapy, we also sought to define epigenetic biomarkers in

whole blood at baseline associated with anti-TNF drug concentrations at week 14. We identify

widespread differences in DNA methylation induced by anti-TNF drug treatment and show that

baseline DNA methylation profiles can predict anti-TNF drug concentration at week 14.

Methods

Study design

The PANTS study is a UK wide, multicentre, prospective observational cohort reporting the

treatment failure rates of the anti-TNF drugs infliximab (originator, Remicade [Merck Sharp &

Dohme, Hertfordshire, UK] and biosimilar, CTP13 [Celltrion, Incheon, South Korea]), and adalimumab

(Humira [AbbVie, Cambridge, MA]) in 1610 anti−TNF-naïve patients with Crohn's disease.

(Supplementary Table 1)

Patients were recruited between February 2013 and June 2016 at the time of first anti-TNF exposure

and studied for 12 months or until drug withdrawal. Eligible patients were aged ≥ 6 years with

objective evidence of active luminal Crohn's disease involving the colon and/or small intestine.

Exclusion criteria included prior exposure to, or contraindications for the use of, anti-TNF therapy.

The choice of anti-TNF was at the discretion of the treating physician and prescribed according to

the licensed dosing schedule. Study visits were scheduled at first dose, week 14, and at weeks 30

and 54. Additional visits were planned for infliximab-treated patients at each infusion and for both

groups at treatment failure or exit.

Treatment failure endpoints were primary non-response at week 14, non-remission at week 54, and

adverse events leading to drug withdrawal.

We used composite endpoints using the Harvey Bradshaw Index (HBI) in adults and the short

paediatric Crohn's disease activity index (sPCDAI) in children, corticosteroid use, and CRP to define

primary non-response (Supplementary Figure 1). Remission was defined as CRP of ≤3 mg/L and HBI

of ≤4 points (sPCDAI ≤15 in children), without corticosteroid therapy or exit for treatment failure.

Variables recorded at baseline were patient demographics (age, sex, ethnicity, comorbidities, height

and weight and smoking status) and IBD phenotype and its treatments (age at diagnosis, disease

duration, Montreal classification, prior medical and drug history, and previous Crohn's disease-

related surgeries). At every visit, disease activity score, weight, current therapy and adverse

events were recorded.

Blood and stool samples were collected at each visit and processed through the central laboratory at

the Royal Devon & Exeter NHS Foundation Trust (https://www.exeterlaboratory.com/) for

haemoglobin, white cell count, platelets, serum albumin, CRP, anti-TNF drug and anti-drug antibody

concentrations, and faecal calprotectin, respectively.

DNA methylation processing

Genomic DNA was extracted from peripheral whole blood using the Qiagen Qiasymphony DNA DSP

midi kit (Qiagen, Ca, USA). Following sodium bisulfite conversion with the Zymo Research EZ-DNA

Methylation kit (Zymo Research, CA USA), DNA methylation was quantified across the genome using

the Illumina Infinium HumanMethylationEPIC (EPIC) BeadChip (Illumina Inc, CA, USA). To negate any

methodological batch effects, individuals were randomised across experimental batches and

samples from the same individual were processed together across all experimental stages.

Data pre-processing and quality control checks

Raw Illumina EPIC data were imported into R (version 3.6.0) using the *bigmelon* package (v1.12.0)[30].

Quality control (QC) checks were performed using the *bigmelon* (v1.12.0)[30] and *minfi* (v1.32.0)[31] R

packages. They included the following steps: we first removed samples by 1) checking median

methylated and unmethylated signal intensities and excluding samples with low intensities (<500) (3

samples excluded), 2) assessing bisulphite conversion efficacy of each sample and excluding samples

with a conversion rate < 80% (9 samples excluded), 3) using the 59 single nucleotide polymorphism

(SNP) probes present on the EPIC array to confirm all matched samples from the same individual

were genetically identical and to check for sample switches or duplications (12 samples excluded), 4)

comparing intensity values from probes located on the X and Y chromosomes to autosomes to

identify sex mismatches (10 samples excluded), 5) visually inspecting the first six principal

components and excluding outliers (none identified), 6) using the pfilter function in the *bigmelon*

(v1.12.0) package to exclude samples where >1% of probes had a detection p-value >0.05 (none

identified). We subsequently removed probes by 7) using the pfilter function in the *bigmelon*

(v1.12.0) package to exclude probes with a bead count <3 or 1% of samples with a detection p-value

> 0.05 (8313 probes) and 8) removal of cross-hybridising probes and those containing a SNP (73,239

probes). Following QC, quantile normalisation was carried out and 784,105 probes were taken

forwards for analysis after exclusion of probes on the Y chromosome.

Sample size and statistical methods

Sample size calculations from the whole PANTS cohort have been reported previously[5]. For this

analysis, we selected whole blood samples from a subset of 385 participants treated with infliximab

and adalimumab aged >16 years, with a baseline CRP ≥4 mg/L and/or calprotectin >100 µg/g who

experienced primary non-response at week 14 and non-remission at week 30 or 54 (n = 99 and 94,

respectively), and an equal number of participants as a comparator group who were classified with

primary response at week 14 and subsequent remission (n = 99 and 93, respectively) for DNA

methylation profiling.

Statistical analyses were undertaken in R 4.1.3 (R Foundation for Statistical Computing, Vienna,

Austria). We included patients with missing clinical variables in analyses for which they had the

necessary data and have specified the sample size for each variable. Continuous data are reported as

median and interquartile range, and discrete data as numbers and percentages. Fisher's exact and

Mann-Whitney U tests were used to identify differences in baseline characteristics between

infliximab-treated and adalimumab-treated patients. Comparative tests were two-tailed and p value

< 0.05 were considered significant unless otherwise stated.

DNA methylation was analysed using beta values, the ratio of methylated intensity to the overall

intensity at each CpG site, which represents the proportion methylation at each site. Because they

influence methylation, *a priori,* we sought to define DNA methylation changes through the course of

the study due to ageing, cigarette smoking and cell composition. Smoking scores were calculated

using a weighted sum approach based on previously published smoking-associated methylation

probes[32]. Epigenetic age was predicted using 353 CpG sites as described by Horvath[21]. Individual cell

proportions of CD4+T cells, CD8+T cells, B cells, granulocytes, and monocytes in each whole blood

sample were estimated using the Houseman reference-based algorithm implemented with functions

in *minfi* (v1.32.0)[31] package. Linear mixed effects models, including time on anti-TNF (study visits in

weeks) as a fixed effect and modelling individual participants with a random intercept, were used to

determine if epigenetic age, smoking behaviour or cell composition were associated with anti-TNF

treatment.

EWAS analyses of anti-TNF treatment, anti-TNF drug concentration and primary non-response were

conducted using linear mixed effects models in this within-subject study, where anti-TNF type and

cell proportions were adjusted for as fixed effects while a random effect (random intercept) was

used to capture the individual level effects. Study visits in weeks, reflecting the duration of anti-TNF

treatment, was included as an interaction term in the model. Patients treated with infliximab and

adalimumab were analysed together to increase the power to detect shared effects. An empirically-

derived p value $< 9 \times 10^{-8}$ was considered significant to control for multiple testing[33]. Pathway

analysis with annotations to Gene Ontology (GO) terms was performed using the *gometh ()* function

in *missMethyl* (v1.28.0)[34] package, which controls for bias arising due to multiple genes being

annotated to a single CpG, and multiple CpGs annotated to a single gene. DMPs were searched in

the EWAS catalog[35] (http://www.ewascatalog.org/, assessed on 15/12/2022) to look for

associations with other common traits. A false discovery rate (FDR) of < 0.05 was considered

significant for pathway analysis and associations in the EWAS catalog. We sought overlapping DMPs

associated with drug levels and primary non-response and correlation of coefficients was

determined using Spearman's test.

Ethical and role of the funding source

The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust. The South West

Research Ethics committee approved the study (REC Reference: 12/SW/0323) in January 2013. The

funders of this study had no role in study design, data collection, data analysis, data interpretation,

or writing of the report. The corresponding author had full access to all the data in the study and had

final responsibility for the decision to submit for publication.

Results

Summary of PANTS DNA methylation dataset

DNA methylation was quantified across the genome in 1,104 whole blood DNA samples from 385

individuals across four study visits (baseline, week 14, week 30, week 54) from the PANTS cohort.

Following a standard quality control pipeline (see Methods), our final dataset included 784,105 DNA

methylation sites quantified in 1,062 samples from 385 participants (Supplementary Figure 1). 87

participants provided samples at all four study visits and the median number of samples per

participant was 3 (interquartile range [IQR] 2 – 3) (Supplementary Table 2).

Overall, 51.7% (199/385) of participants were female, with a median age of 35.7 years (IQR 26.3 -

50.3). 21.2% (81/382) of participants were current smokers and 30.6% (117/382) were former

smokers. The median disease duration was 2.2 years [IQR 0.6 - 9.6] and 50.9% (196/385) and 35.3%

(136/385) of participants were treated with a concomitant immunomodulator and steroids at

baseline, respectively. In total, 51.4% (198/385) of participants were treated with infliximab and

48.6% (187/385) with adalimumab (Table 1). Median infliximab (3.30 mg/L vs 8.09 mg/L, p < 0.001)

and adalimumab (7.70 mg/L vs. 13.35 mg/L, p < 0.001) drug concentrations at week 14 were lower in

patients who experienced primary non-response, as previously observed in the wider cohort[5].

(Supplementary Figure 2).

Anti-TNF treatment is associated with altered blood cell proportions using measures derived from

DNA methylation data

A number of robust statistical classifiers have been developed to derive estimates of environmental

exposures such as tobacco smoking[32], biological age[21] and the proportion of different blood cell

types[36] from whole blood DNA methylation data.

As expected, current and former tobacco smokers had a higher DNA methylation-derived smoking

score at baseline (former smokers 0.2 [IQR -2.0 - 4.1], p < 0.001 and current smokers 6.6 [IQR 3.3 -

9.5], p < 0.001) when compared to never smokers (-2.3 [IQR -3.8 - -1.0]). Over the duration of the

study, DNA methylation smoking score increased (effect size per week 0.019, p < 0.001). When

compared to current smokers, the trajectory of DNA methylation smoking score changed

significantly in former (effect size per week -0.010, p = 0.003), but not current smokers (effect size

per week -0.004, p = 0.262) (Supplementary Figure 3) When stratified by response to anti-TNF

treatment, following anti-TNF treatment, there was no difference in the trajectory of smoking scores

of current smokers (effect size per week - 0.006, p = 0.433) or former smokers (effect size per week -

0.0001, p = 0.986) between those who experienced primary non-response compared to those who

did not.

The epigenetic age of participants measured using the Horvath multi-tissue clock was highly

correlated with chronological age of participants at study entry (r = 0.95, p < 0.001). Over the course

of the study following anti-TNF treatment, epigenetic age changed with time (effect size per week

0.002, p < 0.001). When stratified by response to anti-TNF treatment, however, there was no

difference in the trajectory of change in epigenetic age (effect size per week 0.003, p = 0.71).

(Supplementary Figure 4)

To understand the immune cell changes following anti-TNF treatment, cell proportion estimates

were derived from DNA methylation data. Over time, following anti-TNF treatment, there was a

significant increase in the derived proportions of CD4 T cells (effect size per week 0.0013, p < 0.001),

CD8 T cells (effect size per week 0.0005, p < 0.001), B cells (effect size per week 0.0004, p < 0.001)

and NK cells (effect size per week 0.0001, p = 0.015). (Figure 1) In contrast, the proportion of

monocytes (effect size per week -0.0001, p = 0.025) and granulocytes (effect size per week -0.0023,

p < 0.001) decreased significantly. In patients who experienced primary non-response, the increase

in proportion of B cells (effect size per week -0.0002, p < 0.001) and CD4 T cells (effect size per week

-0.0004, p = 0.048) were less marked over time when compared to those who responded. There was

no difference in the change of proportion of granulocytes (effect size per week 0.0002, p = 0.571).

Changes in biological processes of the immune pathways occur following anti-TNF treatment

Across all patients, 4,999 DMPs (p < 9 x 10^{-8}) annotated to 2,376 unique genes were associated with

anti-TNF treatment (infliximab or adalimumab) regardless of response (Table 2, Figure 2). These

DMPs were significantly enriched for sites becoming hypomethylated over time (63.5%

[3,176/4,999], p < 0.001). Of treatment-associated DMPs annotated to genes (n = 3,504 [70.1%]), the

majority were located in the gene body (67.1% [2,351/3,504]) (Supplementary Figure 5) representing

a significant enrichment compared to the background distribution of probes on the EPIC array

(67.1% vs 29.5%, p < 0.001). The top-ranked DMP associated with anti-TNF treatment was

cg11047325 annotated to the *SOCS3* gene, involved in the negative regulation of the JAK-STAT

pathway and thought to play a role in modulating the outcome of infections and autoimmune

diseases[37] (effect size per week 0.0008, p = 1.91 x 10^{-41}).

Gene ontology (GO) analysis of genes annotated to treatment-associated DMPs identified 108

significant biological pathways (Supplementary Table 3) further implicating the immune response

(immune system process (GO: 0002376, FDR < 0.001), immune response (GO: 0006955, FDR <

0.001), and immune system development (GO:0002520, FDR < 0.001)) alongside pathways related to

blood cell differentiation (haematopoietic or lymphoid organ development (GO:0048534, FDR <

0.001) and haemopoiesis (GO: 0030097, FDR < 0.001)) (Supplementary Figure 6).

DNA methylation in infliximab and adalimumab treated patients

Next, we performed an epigenome-wide association study (EWAS) to identify any DMPs associated

with anti-TNF treatment type. Overall, there were no significant DMPs at baseline between anti-TNF

naïve Crohn's disease patients who were subsequently treated with infliximab or adalimumab.

Irrespective of primary non-response status, we observed 13 DMPs annotated to 9 genes with

significantly different trajectories following treatment with infliximab compared to adalimumab. The

top-ranked DMPs between treatments included cg03446165 [annotated to *MMP25*] (effect size per

week -0.0004, p = 6.78 x 10^{-10}), cg12229367 (effect size per week -0.0003, p = 1.54 x 10^{-9}) and

cg04790662 [annotated to *PAG1*] (effect size per week -0.0005, p = 2.82 x 10^{-9}). (Supplementary

Table 4)

DNA methylation differences at baseline are associated with anti-TNF drug concentration

following treatment

We sought to determine if DNA methylation difference at baseline prior to the start of anti-TNF

treatment were associated with anti-TNF drug concentrations at week 14. We identified 323 DMPs

annotated to 210 genes at baseline associated with anti-TNF drug concentrations at week 14 (Table

3, Figure 3). The top ranked DMP was cg23320029 annotated to the *TNIK* gene (effect size 0.0555, p

= 4.62 x 10^{-15}), encoding the TRAF2 and NCK-interacting kinase, a key regulator in the Wnt signalling

pathway implicated in the modulation of immune response during inflammation[38]. GO analysis of

genes annotated to DMPs associated with anti-TNF drug concentration at week 14, however, did not

identify any FDR (FDR < 0.05) significant pathways.

We intersected the list of DMPs predicting anti-TNF drug concentration following treatment with the

EWAS catalog[35] to identify overlaps with DNA methylation differences associated with other traits

and diseases, finding that 125 (38.7%) DMPs have been previously associated with other common

traits (Supplementary Table 5). The most common shared association (proportion of shared CpGs

compared to DMPs) was with an EWAS of body mass index (23.2%), followed by CRP (11.5%),

smoking (7.4%), alcohol consumption per day (7.1%) and IBD type (6.8%). The associations with

these common traits all had an opposite direction of effect to anti-TNF drug concentration in our

cohort; CpG sites associated with a higher BMI and increased CRP were associated with lower anti-

TNF drug concentrations, in keeping with the known associations with anti-TNF drug concentration

and treatment outcomes[5].

To understand if there was a relationship between anti-TNF drug concentration at week 14 and anti-

TNF treatment response, we performed an EWAS of primary non-response to anti-TNF, and

identified 48 DMPs annotated to 36 genes at baseline. Of these, 20 DMPs were associated with both

anti-TNF drug concentration and primary non-response to anti-TNF (Supplementary Table 6). These

DMPs include cg27216853 [*CYS1*] (effect size to drug concentration -0.0371 vs effect size to primary

non-response 0.0245), cg23606775 [*CLSTN1*] (-0.0220 vs 0.0133) and cg18138532 [*UPF2*] (-0.0273 vs

0.0157). Overall, there was a strong correlation of the coefficients (Spearman's rho = -0.94, p <

0.001) (Figure 4), suggesting a relationship between DMPs associated with lower anti-TNF drug

concentration and primary non-response.

Longitudinal changes in DNA methylation differ in patients with primary non-response to anti-TNF

treatment

Following anti-TNF treatment, intra-individual changes in DNA methylation was significantly

different between those who experienced primary non-response to anti-TNF compared to those

who did not at 5 DMPs. These sites were cg07839457 [annotated to *NLRC5*] (effect size per week -

0.0007, p = 1.92 x 10^{-13}), cg11047325 [annotated to *SOCS3*] (-0.0007, p = 3.70 x 10^{-11}), cg15022400

[annotated to *TRIM69*] (-0.0003, p = 3.39 x 10^{-9}), cg25867318 [annotated to *STAT3*] (-0.0004, p =

6.06 x 10^{-8}) and cg08950751 [annotated to *AIP*] (-0.0003, p = 6.82 x 10^{-8}) (Supplementary Table 7).

The top ranked DMP following anti-TNF treatment cg11047325 annotated to *SOCS3* involved in

regulation of the JAK-STAT pathway was again identified.

Discussion

Key results

In whole blood, we observed almost 5,000 DMPs annotated to >2,000 genes that are associated with

anti-TNF therapy, with the genes annotated to these sites being enriched for biological processes

related to immune system processes. 323 DMPs annotated to 210 genes were associated with anti-

TNF drug concentration at week 14 and we observed an overlap between differentially methylated

probes associated with drug concentrations and primary non-response.

Interpretation

It is perhaps unsurprising, that treatment with the anti-TNF monoclonal antibodies infliximab and

adalimumab led to a significant number of differentially methylated probes across multiple genes

that were enriched in immune system pathways. Overall, however, only 13 DMPs were found when

comparing infliximab- and adalimumab-treated patients, suggesting that there is an anti-TNF

treatment class effect and that both drugs exert a similar effect upon levels of DNA methylation. A

similar conclusion was made from a study of patients with rheumatoid arthritis treated with several

different anti-TNFs including adalimumab, certolizumab, etanercept, golimumab and infliximab, with

no DMPs were identified between different anti-TNF subtypes[39].

The immune cell changes and intracellular signalling pathways in peripheral blood and intestinal

tissue following treatment with anti-TNF in patients with IBD is still unclear[40]. Unlike a previous study

of 14 patients with IBD[41], following anti-TNF treatment, we did not observe a change in derived

granulocyte proportions between non-responders and responders, but noted differences in B cells

and CD4 T cells. Derived cell proportions at baseline were, however, not useful as a biomarker of

anti-TNF non-response.

About a third (38.7%) of the DMPs associated with low drug concentrations were linked to other

common traits including body mass index, smoking, and CRP that in the PANTS cohort were

associated with drug concentration and anti-TNF treatment failure[5]. It is plausible that these DMPs

could be used as blood biomarkers independent of clinical traits to predict inter-individual variability

in anti-TNF drug concentration, allowing early effective anti-TNF dose prescribing. Our findings that

the DMPs were enriched in gene bodies may suggest a more complex mechanism apart from gene

transcription in their role underlying anti-TNF treatment response. The role of gene body

methylation is still widely debated, and while they have been associated with the regulation of gene

expression, they have a more complex role in suppressing aberrant gene transcription and regulating

alternative splicing[42]. With the advancement of single-cell sequencing technologies, the study of

specific cell types in both disease specific intestinal tissue[43] and peripheral whole blood[44]perhaps

based on our data focussing on the role of B- and CD4$^+$ T cells, may provide further insights into the

molecular mechanisms underlying anti-TNF treatment failure.

Whilst there was a strong correlation of effect between DMPs associated with lower drug

concentration at week 14 and primary non-response, the modest effect sizes mean that these

markers are unlikely to be useful as a diagnostic predictor of primary non-response in individual

patients. Why primary non-response is so difficult to predict in patients with IBD is unclear. Few of

the so-called precision medicine biomarkers to facilitate the right drug, to the right patient, at the

right time have been replicated or translated to clinical care. There are a number of possible reasons

for this. Firstly, the challenges of defining primary non-response in the absence of endoscopic

outcome data. In the PANTS study, we used a pragmatic composite outcome closely linked to

routine clinical care that included patient symptoms assessed using a validated severity scores and

serum CRP. However, there is poor concordance between symptoms and biomarkers and mucosal

inflammation. Patients with Crohn's disease may also complain of symptoms suggestive of active

disease because of overlapping irritable bowel syndrome, bile acid malabsorption and or small

intestinal overgrowth. Further interpretation of potential markers across studies is challenging due

to differences in study design, inclusion criteria, improvements in experimental and computational

methods over time, and critically confounding by sampling of different tissues and cellular

heterogeneity. These challenges may explain why we were unable to replicate here the previous

associations with oncostatin M (*OSM*)[9,10] and triggering receptor expressed on myeloid cells (*TREM-*

1)[11,12] identified as potential biomarkers predicting non-response to anti-TNF treatment. Our data

argues against the presence of a single epigenetic biomarker in whole blood with clinical utility.

Our observations that higher DNA methylation epigenetic smoking score and smoking status, and

epigenetic age of participants and chronological age were highly positively correlated internally

validates our DNA methylation processing and quality control methods supporting subsequent

findings against clinical outcomes. Interestingly, increase in smoking score was observed in all groups

regardless of smoking status over time, but was significantly less in former smokers compared to

never smokers. Prior longitudinal studies of DNA methylation changes following smoking cessation

have reported conflicting results[37,38], although varying follow-up times and the study of different

populations makes it difficult to compare across studies. Whether the DNA methylation changes

following smoking cessation have an impact on anti-TNF drug concentration or outcomes in patients

with Crohn's disease requires further investigation.

Limitations and generalisability

We acknowledge some important limitations of our work. First, our outcome data could be

strengthened with endoscopic outcomes. However, we observed a significant association between

clinical outcomes at week 14 and week 54 and faecal calprotectin, which has been shown to closely

correlate with endoscopic findings. Second, we measured DNA methylation from whole blood which

is likely to be confounded by differences in individual cell proportions. Although we included derived

cell proportions as a covariate in our statistical models, this is unlikely to fully control for cellular

changes which may be better controlled for by expanded panels of blood cell types or single-cell

analyses. Whether similar changes also occur in the target tissues in the small and large intestine is

unknown. Third, our findings should be validated in an independent cohort prior to translation into

clinical practice.

The PANTS study recruited patients from across the UK, and we believe our findings will be

generalisable to patients with Crohn's disease treated with an anti-TNF across other western

populations. Further work is required to determine if these findings are found in other non-western

populations, and indeed in other populations of patients with IBD such as those with ulcerative

colitis, and in non-IBD patients treated with an anti-TNF.

Conclusion

Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at

week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF

therapy.

Acknowledgements

S.L. is supported by a Wellcome GW4-CAT fellowship (222850/Z/21/Z). N.C. acknowledges support from Crohn's and Colitis UK. This study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The authors would like to acknowledge James Butler for facilitating this collaboration and Samantha Lent, Justin Wade Davis, Elina Regan, Stephen Abel, Elizabeth Asque and Areej Ammar in the preparation of this manuscript. We also acknowledge John Kirkwood and Anna Barnes from the NIHR Clinical Research Facility for their support with sample preparation, and the study coordinators of the Exeter IBD Research Group, Marian Parkinson and Helen Gardner-Thorpe for their ongoing administrative support to the study.

Funding

PANTS is an investigator-led study funded by CORE (renamed Guts UK in 2018), the research charity of the British Society of Gastroenterology, and by unrestricted educational grants from AbbVie Inc, USA, Merck Sharp & Dohme Ltd, UK, NAPP Pharmaceuticals Ltd, UK, Pfizer Ltd, USA, Celltrion Healthcare, South Korea, and Cure Crohn's Colitis (Scottish IBD Charity). DNA methylation processing was supported through a sponsored research agreement with AbbVie Inc. The drug and anti-drug antibody assays were provided at reduced cost by Immundiagnostik AG. Laboratory tests were undertaken by the Exeter Blood Sciences Laboratory at the Royal Devon & Exeter National Health Service Trust (https://www.exeterlaboratory.com). The sponsor of the PANTS study is the Royal Devon and Exeter National Health Service Foundation Trust. None of the listed funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and decision to submit the manuscript for publication.

Conflict of Interest

Simeng Lin reports non-financial support from Pfizer outside the submitted work. Mark Reppell,

Jeffrey F Waring, Valerie Pivorunas, Nizar Smaoui, Heath Guay are employees of AbbVie and may

own stock/options. Nicholas A. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from

Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support

from Immundiagnostik; grants and non-financial support from AbbVie, grants and personal fees from

Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, and

personal fees and non-financial support from Dr Falk, outside the submitted work. James R.

Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from

Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik

outside the conduct of the study. Tariq Ahmad reports grants and non-financial support from F.

Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from

Galapagos NV and non-financial support from Immundiagnostik; personal fees from Biogen inc,

grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from

Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead,

personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from

Genentech and non-financial support from Tillotts, outside the submitted work. Eilis Hannon, Claire

Bewshea, Neil Chanchlani and Jonathan Mill declare no competing interests.

Author Contributions

NAK, JRG, TA participated in the conception and design of this study. CB was the project manager

and coordinated patient recruitment. SL, EH, NS, JFW, VP, HG, CB, NC, BB, NAK, JRG, JM, TA were

involved in the acquisition, analysis or interpretation of data. Data analysis was done by SL and EH.

Drafting of the manuscript was done by SL, EH, NS, JFW, VP, HG, NC, BB, NAK, JRG, JM, TA. TA

obtained the funding for the study. All the authors contributed to the critical review and final

approval of the manuscript. JM and TA have verified the underlying data.

Data availability statement

Individual participant de-identified data that underlie the results reported in this article will be

available immediately after publication for a period of 5 years. The data will be made available to

investigators whose proposed use of the data has been approved by an independent review

committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be

directed to tariq.ahmad1@nhs.net. To gain access data requestors will need to sign a data access

agreement.

References

1.   Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy

450   and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review

451   and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 Dec 1;6(12):1002–14.

452   2.   Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in

453   induction and maintenance of remission in luminal Crohn's disease: systematic review and

454   network meta-analysis. Gut [Internet]. 2022 Jul 30 [cited 2022 Sep 8];0:gutjnl-2022-328052.

455   Available from: https://gut.bmj.com/content/early/2022/07/29/gutjnl-2022-328052

456   3.   Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review

457   with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing

458   hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther

459   [Internet]. 2017 Jan 1 [cited 2022 Sep 9];45(1):3–13. Available from:

460   https://pubmed.ncbi.nlm.nih.gov/27862107/

461   4.   Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for

462   therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution

463   in the definition and management of primary nonresponse. Inflamm Bowel Dis [Internet].

464   2015 Jan;21(1):182–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25222660

465   5.   Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-

466   TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a

467   prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;1253(19):1–13.

468   6.   Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, et al. HLA-DQA1*05

469   Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and

470   Adalimumab in Patients With Crohn's Disease. Gastroenterology [Internet]. 2020;158(1):189–

471   99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31600487

7.   Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dashboard-Driven

Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces

Immunogenicity. Inflamm Bowel Dis [Internet]. 2022 Sep 1 [cited 2022 Dec 20];28(9):1375–

85. Available from: https://pubmed.ncbi.nlm.nih.gov/34978325/

8.   Lawrence S, Faytrouni F, Harris RE, Irvine M, Carrion E, Scott G, et al. Optimized Infliximab

Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard

Induction Dosing. J Pediatr Gastroenterol Nutr [Internet]. 2022 Nov 1 [cited 2022 Dec

20];75(5):601–7. Available from: https://pubmed.ncbi.nlm.nih.gov/36048178/

9.   West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives

intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy

in patients with inflammatory bowel disease. Nat Med [Internet]. 2017 [cited 2022 Sep

9];23(5):579–89. Available from: https://pubmed.ncbi.nlm.nih.gov/28368383/

10.   Verstockt S, Verstockt B, MacHiels K, Vancamelbeke M, Ferrante M, Cleynen I, et al.

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic

Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis [Internet]. 2021 Oct 1 [cited

2022 Sep 9];27(10):1564–75. Available from: https://pubmed.ncbi.nlm.nih.gov/33624092/

11.   Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, et al. Cell-

centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and

blood of patients with IBD. Gut [Internet]. 2019 Apr 1 [cited 2022 Sep 9];68(4):604–14.

Available from: https://gut.bmj.com/content/68/4/604

12.   Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, et al. Low TREM1

expression in whole blood predicts anti-TNF response in inflammatory bowel disease.

EBioMedicine [Internet]. 2019 Feb 1 [cited 2022 Sep 9];40:733. Available from:

/pmc/articles/PMC6413341/

13.   Sudhakar P, Alsoud D, Wellens J, Verstockt S, Arnauts K, Verstockt B, et al. Tailoring Multi-

497   omics to Inflammatory Bowel Diseases: All for One and One for All. J Crohn's Colitis [Internet].

498   2022 Aug 30 [cited 2022 Dec 20];16(8):1306–20. Available from:

499   https://academic.oup.com/ecco-jcc/article/16/8/1306/6527686

500   14.   Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC, et al. Results of the

501   Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Disease Outcome and

502   Response to Therapy. J Crohn's Colitis [Internet]. 2021 Sep 25 [cited 2022 Dec

503   19];15(9):1431–42. Available from: https://academic.oup.com/ecco-

504   jcc/article/15/9/1431/6175314

505   15.   Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and

506   medicine. Lancet. 2018 Sep 1;392(10149):777–86.

507   16.   Schübeler D. Function and information content of DNA methylation. Nat 2015 5177534

508   [Internet]. 2015 Jan 14 [cited 2023 Feb 1];517(7534):321–6. Available from:

509   https://www.nature.com/articles/nature14192

510   17.   Wan J, Oliver VF, Wang G, Zhu H, Zack DJ, Merbs SL, et al. Characterization of tissue-specific

511   differential DNA methylation suggests distinct modes of positive and negative gene

512   expression regulation. BMC Genomics [Internet]. 2015 Feb 5 [cited 2023 Feb 1];16(1):1–11.

513   Available from: https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-015-

514   1271-4

515   18.   de Mendoza A, Nguyen TV, Ford E, Poppe D, Buckberry S, Pflueger J, et al. Large-scale

516   manipulation of promoter DNA methylation reveals context-specific transcriptional responses

517   and stability. Genome Biol [Internet]. 2022 Dec 1 [cited 2023 Feb 1];23(1):1–31. Available

518   from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02728-5

19.   Villicaña S, Bell JT. Genetic impacts on DNA methylation: research findings and future

perspectives. Genome Biol 2021 221 [Internet]. 2021 Apr 30 [cited 2023 Feb 1];22(1):1–35.

Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-021-

02347-6

20.   Hannon E, Knox O, Sugden K, Burrage J, Wong CCY, Belsky DW, et al. Characterizing genetic

and environmental influences on variable DNA methylation using monozygotic and dizygotic

twins. PLOS Genet [Internet]. 2018 Aug 1 [cited 2022 Sep 9];14(8):e1007544. Available from:

https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1007544

21.   Horvath S. DNA methylation age of human tissues and cell types. Genome Biol [Internet].

2013 Oct 21 [cited 2022 Sep 8];14(10):1–20. Available from:

https://genomebiology.biomedcentral.com/articles/10.1186/gb-2013-14-10-r115

22.   Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease

course and insights into the aetiology of its effect. J Crohn's Colitis [Internet]. 2014 Aug 1

[cited 2022 Sep 30];8(8):717–25. Available from: https://academic.oup.com/ecco-

jcc/article/8/8/717/530121

23.   Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-Wide Association Studies for common

human diseases. Nat Rev Genet [Internet]. 2011 Aug [cited 2023 Feb 1];12(8):529. Available

from: /pmc/articles/PMC3508712/

24.   Birney E, Smith GD, Greally JM. Epigenome-wide Association Studies and the Interpretation of

Disease -Omics. PLOS Genet [Internet]. 2016 Jun 1 [cited 2023 Feb 1];12(6):e1006105.

Available from:

https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006105

25.   McDermott E, Ryan EJ, Tosetto M, Gibson D, Burrage J, Keegan D, et al. DNA Methylation

Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis. J

Crohns Colitis [Internet]. 2016 Jan 1 [cited 2022 Sep 8];10(1):77–86. Available from:

544    https://pubmed.ncbi.nlm.nih.gov/26419460/

545 26. Somineni HK, Venkateswaran S, Kilaru V, Marigorta UM, Mo A, Okou DT, et al. Blood-Derived

546    DNA Methylation Signatures of Crohn's Disease and Severity of Intestinal Inflammation.

547    Gastroenterology [Internet]. 2019 Jun 1 [cited 2022 Sep 8];156(8):2254-2265.e3. Available

548    from: https://pubmed.ncbi.nlm.nih.gov/30779925/

549 27. Fisel P, Schaeffeler E, Schwab M. DNA Methylation of ADME Genes. Clin Pharmacol Ther

550    [Internet]. 2016 May 1 [cited 2022 Dec 20];99(5):512–27. Available from:

551    https://onlinelibrary.wiley.com/doi/full/10.1002/cpt.343

552 28. Nair N, Plant D, Plant D, Verstappen SM, Verstappen SM, Isaacs JD, et al. Differential DNA

553    methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology

554    (Oxford) [Internet]. 2020 Jun 1 [cited 2022 Sep 9];59(6):1364–71. Available from:

555    https://pubmed.ncbi.nlm.nih.gov/31598719/

556 29. Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, et al. Differential Methylation as a

557    Biomarker of Response to Etanercept in Patients with Rheumatoid Arthritis. Arthritis

558    Rheumatol [Internet]. 2016 Jun 1 [cited 2022 Sep 9];68(6):1353–60. Available from:

559    https://onlinelibrary.wiley.com/doi/full/10.1002/art.39590

560 30. Gorrie-Stone TJ, Smart MC, Saffari A, Malki K, Hannon E, Burrage J, et al. Bigmelon: tools for

561    analysing large DNA methylation datasets. Bioinformatics [Internet]. 2019 Mar 15 [cited 2022

562    Sep 8];35(6):981–6. Available from:

563    https://academic.oup.com/bioinformatics/article/35/6/981/5078475

564 31. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a

565    flexible and comprehensive Bioconductor package for the analysis of Infinium DNA

566    methylation microarrays. Bioinformatics [Internet]. 2014 May 15 [cited 2022 Sep

567    8];30(10):1363–9. Available from: https://pubmed.ncbi.nlm.nih.gov/24478339/

568   32.   Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. Differences in smoking

569   associated DNA methylation patterns in South Asians and Europeans. Clin Epigenetics

570   [Internet]. 2014 Feb 3 [cited 2022 Sep 8];6(1):1–10. Available from:

571   https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/1868-7083-6-4

572   33.   Mansell G, Gorrie-Stone TJ, Bao Y, Kumari M, Schalkwyk LS, Mill J, et al. Guidance for DNA

573   methylation studies: statistical insights from the Illumina EPIC array. BMC Genomics

574   [Internet]. 2019 May 14 [cited 2022 Sep 8];20(1). Available from:

575   /pmc/articles/PMC6518823/

576   34.   Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package for analyzing data from

577   Illumina's HumanMethylation450 platform. Bioinformatics [Internet]. 2016 Jan 15 [cited 2022

578   Sep 8];32(2):286–8. Available from:

579   https://academic.oup.com/bioinformatics/article/32/2/286/1744111

580   35.   Battram T, Yousefi P, Crawford G, Prince C, Sheikhali Babaei M, Sharp G, et al. The EWAS

581   Catalog: a database of epigenome-wide association studies. Wellcome Open Res 2022 741

582   [Internet]. 2022 May 31 [cited 2022 Sep 8];7:41. Available from:

583   https://wellcomeopenresearch.org/articles/7-41

584   36.   Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA

585   methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics

586   [Internet]. 2012 May 8 [cited 2023 Feb 1];13(1):1–16. Available from:

587   https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-13-86

588   37.   Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front

589   Immunol. 2014 Feb 19;5(FEB):58.

590   38.   Jridi I, Canté-Barrett K, Pike-Overzet K, Staal FJT. Inflammation and Wnt Signaling: Target for

591   Immunomodulatory Therapy? Front Cell Dev Biol. 2021 Feb 4;8:1854.

39.   Julià A, Gómez A, López-Lasanta M, Blanco F, Erra A, Fernández-Nebro A, et al. Longitudinal

analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis

factor inhibitor therapy in rheumatoid arthritis. eBioMedicine [Internet]. 2022 Jun 1 [cited

2022 Sep 30];80. Available from:

http://www.thelancet.com/article/S2352396422002341/fulltext

40.   Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in

Inflammatory Bowel Disease. J Crohn's Colitis [Internet]. 2016 Aug 1 [cited 2022 Dec

22];10(8):989–97. Available from: https://academic.oup.com/ecco-

jcc/article/10/8/989/2392174

41.   Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, et al. Longitudinal multi-omics analysis

identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel

disease. Genome Med [Internet]. 2022 Dec 1 [cited 2022 Dec 22];14(1):1–20. Available from:

https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01112-z

42.   Wang Q, Xiong F, Wu G, Liu W, Chen J, Wang B, et al. Gene body methylation in cancer:

molecular mechanisms and clinical applications. Clin Epigenetics 2022 141 [Internet]. 2022

Nov 28 [cited 2022 Dec 23];14(1):1–14. Available from:

https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-022-01382-9

43.   Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, et al. Single-Cell Analysis of

Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to

Anti-TNF Therapy. Cell [Internet]. 2019 Sep 5 [cited 2022 Dec 22];178(6):1493-1508.e20.

Available from: http://www.cell.com/article/S0092867419308967/fulltext

44.   Peres RS, Thomas T, Friedrich M, Pohin M, Pearson C, Ferreira RC, et al. Anti-TNF-induced IL-

27 modulates regulatory T cell responses in patients with IBD that respond to therapy.

bioRxiv [Internet]. 2022 Nov 21 [cited 2022 Dec 22];2022.11.21.517257. Available from:

https://www.biorxiv.org/content/10.1101/2022.11.21.517257v1

Figure Legends

Figure 1: Change in derived cell proportions following treatment with anti-TNF. Predicted derived

cell proportions over time estimated from the regression analysis is represented in solid blue lines,

and observed cell proportions in faded lines. P value represents the change in individual cell

proportions over time.

Figure 2: Manhattan plot of CpG sites associated with change over time following anti-TNF drug

exposure regardless of treatment outcome. The top 10 differentially methylated probes with

annotations are labelled in the plot. The grey horizontal line represents the significant p value

threshold of 9×10^{-8}.

Figure 3: Manhattan plot of CpG sites at baseline associated with anti-TNF drug concentration at

week 14. The top 10 CpG sites with their associated gene annotations are labelled in brackets. The

grey horizontal line represents the significant p value threshold of 9×10^{-8}.

Figure 4: Coefficients of DMPs associated with anti-TNF drug concentration at week 14 and primary

non-response. Coefficients represent the beta values of each CpG from linear mixed effects model to

each outcome. Spearman's rho correlation of the coefficients calculated for those that were

associated with both anti-TNF drug concentration and primary non-response, and the remaining that

were only significant to anti-TNF drug concentration. Abbreviations: PNR = primary non-response.

Variable	Level	adalimumab	infliximab	Overall	p
n		187	198	385	
Age at first dose		37.19 (26.56 - 51.15)	35.25 (25.57 - 49.49)	35.69 (26.34 - 50.26)	0.466
Sex	Female	47.06% (88/187)	56.06% (111/198)	51.69% (199/385)	0.083
	Male	52.94% (99/187)	43.94% (87/198)	48.31% (186/385)	
Ethnicity	White	94.12% (176/187)	94.95% (188/198)	94.55% (364/385)	0.933
	South Asian	2.14% (4/187)	2.02% (4/198)	2.08% (8/385)	
	Other	3.74% (7/187)	3.03% (6/198)	3.38% (13/385)	
Smoking history	Current	17.20% (32/186)	25.00% (49/196)	21.20% (81/382)	0.163
	Ex	33.33% (62/186)	28.06% (55/196)	30.63% (117/382)	
	Never	49.46% (92/186)	46.94% (92/196)	48.17% (184/382)	
Disease duration		2.80 (0.61 - 9.53)	2.08 (0.53 - 9.52)	2.17 (0.56 - 9.53)	0.483
Montreal location classification	L1	31.52% (58/184)	29.44% (58/197)	30.45% (116/381)	0.956
	L2	25.54% (47/184)	26.90% (53/197)	26.25% (100/381)	
	L3	42.39% (78/184)	43.15% (85/197)	42.78% (163/381)	
	L4	0.54% (1/184)	0.51% (1/197)	0.52% (2/381)	
Montreal behaviour classification	B1	59.24% (109/184)	63.96% (126/197)	61.68% (235/381)	**0.035**
	B2	35.33% (65/184)	25.38% (50/197)	30.18% (115/381)	
	B3	5.43% (10/184)	10.66% (21/197)	8.14% (31/381)	
Immunomodulator use at baseline	TRUE	52.94% (99/187)	48.99% (97/198)	50.91% (196/385)	0.476
Steroid use at baseline	TRUE	29.41% (55/187)	40.91% (81/198)	35.32% (136/385)	**0.019**
C-reactive protein (mg/L)		8.00 (4.00 - 19.50)	12.00 (5.00 - 32.00)	10.00 (5.00 - 24.00)	**0.013**
HBI score		5.00 (3.00 - 8.00)	6.00 (3.00 - 9.50)	5.00 (3.00 - 9.00)	0.256
Faecal calprotectin (ug/g)		307.00 (159.50 - 599.00)	481.00 (251.00 - 881.50)	365.00 (188.00 - 726.00)	**0.001**
Haemoglobin (g/L)		129.50 (120.00 - 140.00)	125.00 (112.00 - 135.00)	128.00 (116.00 - 137.00)	**0.002**
White cell count (x 10^9 cells per L)		7.90 (6.20 - 10.20)	8.56 (6.60 - 10.70)	8.23 (6.40 - 10.40)	0.166

639
640 **Table 1: Characteristics at baseline of participants stratified by type of anti-TNF**
641

CpG	chr	pos	Relation to Island	Gene name	Gene group	Coefficient (per week)	P value
cg11047325	17	76354934	Island	SOCS3	Body	0.0008	1.91E-41
cg17501210	6	166970252	OpenSea	RPS6KA2	Body	0.0007	1.40E-38
cg19748455	17	76274856	OpenSea	LOC100996291	TSS1500	0.0008	2.55E-37
cg00840791	19	16453259	OpenSea			0.0011	1.02E-35
cg12992827	3	101901234	OpenSea			0.0010	2.23E-33
cg04051206	17	17750855	OpenSea	TOM1L2	3'UTR	0.0005	4.19E-31
cg03546163	6	35654363	N_Shore	FKBP5	5'UTR	0.0012	4.87E-31
cg01526748	3	191930926	OpenSea	FGF12	Body	-0.0005	1.97E-30
cg13074526	17	76274743	OpenSea	LOC100996291	TSS200	0.0008	2.32E-30
cg18608055	19	1130866	OpenSea	SBNO2	Body	0.0008	4.57E-30

643   **Table 2: Top 10 differentially methylated probes associated with anti-TNF treatment over time**

CpG	chr	pos	Relation to Island	Gene name	Gene group	Coefficient (per week)	P value
cg23320029	3	171004750	OpenSea	TNIK	Body	0.0555	4.62E-15
cg16500036	7	68983906	OpenSea			-0.0409	1.61E-14
cg18513344	3	195531298	OpenSea	MUC4	Body	0.0299	4.90E-14
cg21635197	6	135405808	OpenSea			0.0389	8.71E-13
cg22870160	1	231830793	OpenSea	DISC1	Body	-0.0376	1.23E-12
cg03403209	16	29666641	OpenSea			-0.0247	1.51E-12
cg07856599	1	227151843	OpenSea	ADCK3	Body	-0.0411	6.82E-12
cg01950011	8	37396511	OpenSea			-0.0213	8.00E-12
cg27216853	2	10205672	OpenSea	CYS1	Body	-0.0371	8.79E-12
cg02011576	3	38060265	OpenSea	PLCD1	Body	-0.0387	8.82E-12

645 **Table 3: Top 10 differentially methylated probes at baseline associated with anti-TNF drug**
646 **concentration at week 14**

647
648 Figure 1: Change in derived cell proportions following treatment with anti-TNF. Predicted derived

649 cell proportions over time estimated from the regression analysis is represented in solid blue lines,

650 and observed cell proportions in faded lines. P value represents the change in individual cell

651 proportions over time.

653
Figure 2: Manhattan plot of CpG sites associated with change over time following anti-TNF drug

exposure regardless of treatment outcome. The top 10 differentially methylated probes with

annotations are labelled in the plot. The grey horizontal line represents the significant p value

threshold of 9×10^{-8}.

Figure 3: Manhattan plot of CpG sites at baseline associated with anti-TNF drug concentration at

week 14. The top 10 CpG sites with their associated gene annotations are labelled in brackets. The

grey horizontal line represents the significant p value threshold of 9×10^{-8}.

Figure 4: Coefficients of DMPs associated with anti-TNF drug concentration at week 14 and primary

non-response. Coefficients represent the beta values of each CpG from linear mixed effects model to

each outcome. Spearman's rho correlation of the coefficients calculated for those that were

associated with both anti-TNF drug concentration and primary non-response, and the remaining that

were only significant to anti-TNF drug concentration. Abbreviations: PNR = primary non-response.